In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Valixa’s Pediatric Indication Filed for CMV Infection in Organ Transplant
March 1, 2018
- Kaken Grants Rights for Psoriasis Drug Candidate to Valeant
March 1, 2018
- MSD Seeks Japan Approval of Broad-Spectrum Antibiotic
March 1, 2018
- Takeda Files Japan NDA for Relugolix in Uterine Fibroids
March 1, 2018
- Janssen, Japan IBD Society Ink MOU on Crohn’s Disease Registry Study
March 1, 2018
- Hisamitsu’s Transdermal Parkinson’s Drug Hits Primary Endpoint
February 28, 2018
- FDA, EMA Accept Lusutrombopag Submissions, Priority Status Given in US: Shionogi
February 28, 2018
- Daiichi Sankyo Seeks Japan Approval for Hypertension Med Esaxerenone
February 28, 2018
- Kissei Makes Full Foray into IBD Arena with Rectabul, Set to Enrich “Unmet Needs” Portfolio
February 27, 2018
- Daiichi Sankyo to Set Up Specialty Marketing Unit for Oncology Products
February 27, 2018
- Sumitomo Dainippon, JCR Ink License Pact for BBB-Based CNS Drug Candidate
February 27, 2018
- Kyowa Kirin’s Burosumab Earns Conditional Approval in Europe
February 27, 2018
- Sumitomo Dainippon Sues 15 More Companies over Latuda Patent
February 27, 2018
- Liquid Tank Exploded at Kitasato Daiichi Sankyo Vaccine, No Pathogens Escaped
February 27, 2018
- 1st–in-Human Trial Begins for ADC DS-1062 in NSCLC: Daiichi Sankyo
February 26, 2018
- Mitsubishi Tanabe to Complete PIII for Plant-Derived Flu Vaccine in April, Obtain Top-Line Data around Summer
February 26, 2018
- Nomura Picked as Next Chief of Sumitomo Dainippon, Vows to Build Peripheral Healthcare Biz
February 26, 2018
- Sid Singh Named as New President of GSK Consumer Healthcare Japan
February 26, 2018
- Diagnogreen Applied for Evaluation of Blood Flow: Daiichi Sankyo
February 23, 2018
- Fujifilm to Set Up New Manufacturing Facility for Liposome Drugs, Operation Launch Targeted in Feb. 2020
February 23, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…